Neuronal Plasticity

The use of advanced technological solutions (“neurotechnologies”) can improve the clinical outcomes of neurorehabilitation after stroke. Here, Micera et al. propose a paradigm shift that is based on a deep understanding of the basic mechanisms of natural stroke recovery and technology-assisted neurorehabilitation to improve the clinical effectiveness of neurotechnology.
Here, Nestler and Lüscher link addiction circuits to epigenetic mechanisms that are engaged by drug exposure or reflect life experience. These molecular alterations may not only explain the basis of drug-evoked synaptic plasticity, but may also help understand individual addiction vulnerability.
Altered synaptic structure and function is a major hallmark of fragile X syndrome (FXS), autism spectrum disorders (ASDs), and other intellectual disabilities (IDs), which are therefore classified as synaptopathies. FXS and ASDs, while clinically and genetically distinct, share significant comorbidity, suggesting that there may be a common molecular and/or cellular basis, presumably at the synapse.